Genome-wide CRISPR screen identifies BUB1 kinase as a druggable vulnerability in malignant pleural mesothelioma
Abstract Malignant pleural mesothelioma (MPM) is a rare yet highly aggressive malignancy with a severe prognosis. Compounded by the lack of effective treatment modalities, MPM remains a formidable health challenge. Therefore, the identification of actionable liabilities is critical for advancing pre...
Saved in:
| Main Authors: | Ece Cakiroglu, Sude Eris, Ozden Oz, Gökhan Karakülah, Serif Senturk |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-04-01
|
| Series: | Cell Death and Disease |
| Online Access: | https://doi.org/10.1038/s41419-025-07587-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Integrative multi-omics identifies AP-1 transcription factor as a targetable mediator of acquired osimertinib resistance in non-small cell lung cancer
by: Bengisu Dayanc, et al.
Published: (2025-05-01) -
KRAS signaling in malignant pleural mesothelioma
by: Antonia Marazioti, et al.
Published: (2021-12-01) -
A Diagnostic Approach to Malignant Pleural Mesothelioma
by: Avinash Aujayeb, et al.
Published: (2025-06-01) -
Malignant pleural mesothelioma with rarely seen metastases
by: Elif Şenocak Taşçı, et al.
Published: (2017-12-01) -
Case report: targeted therapy of malignant pleural mesothelioma with anaplastic lymphoma kinase receptor tyrosine kinase gene fusion mutation by crizotinib
by: Yufeng Wu, et al.
Published: (2024-11-01)